Showing results (71-80 of 86) with videos related to
Sort By:
Pageof 9
The Lancet. Infectious Diseases|August 16, 2025
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trialLaina D Mercer, Arlene C Seña, E Ross Colgate, et al.Nature Communications|March 30, 2024
Adhesion energy controls lipid binding-mediated endocytosisRaluca Groza, Kita Valerie Schmidt, Paul Markus Müller, et al.Lancet (London, England)|December 10, 2022
Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trialKhaelqu Zaman, Ananda S Bandyopadhyay, Masuma Hoque, et al.Journal of Medicinal Chemistry|November 19, 2025
Calcium Competitive Inhibition of Langerin by ThiazolopyrimidinonesYunzhan Ning, Nina-Louisa Efrém, Machoud Amoussa, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2025
Intestinal mucosal immune responses to novel oral poliovirus vaccine type 2 in healthy newbornsAudrey Godin, Elizabeth B Brickley, Ruth I Connor, et al.Journal of Virology|April 10, 2015
The Greater Affinity of JC Polyomavirus Capsid for α2,6-Linked Lactoseries Tetrasaccharide c than for Other Sialylated Glycans Is a Major Determinant of InfectivityLuisa J Ströh, Melissa S Maginnis, Bärbel S Blaum, et al.Lancet Regional Health. Americas|July 22, 2022
Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological surveyGabriel Trueba, Vishali Jeyaseelan, Lazaro Lopez, et al.Proceedings of the National Academy of Sciences of the United States of America|September 19, 2018
Influenza hemagglutinin membrane anchorDonald J Benton, Andrea Nans, Lesley J Calder, et al.Vaccine|February 6, 2023
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized studyRahsan Erdem, Ilse De Coster, Kanchanamala Withanage, et al.Vaccine|August 31, 2023
Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trialCynthia J Snider, Khalequ Zaman, Amanda L Wilkinson, et al.Pageof 9